EBS-Lassa
/ Emergent Biosolutions
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 15, 2025
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.
(PubMed, Vaccine)
- "Together, these studies supported a first-in-human dose-escalation, safety, and immunogenicity clinical study. This paper uses a viral vector vaccine safety template developed by the Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group to review the features of the rVSV-vectored EBS-LASV vaccine candidate and provides a high-level summary of safety findings from preclinical studies and the Phase 1 clinical study."
Benefit-risk assessment • Journal • Infectious Disease
September 02, 2024
Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus.
(PubMed, Vaccines (Basel))
- "No toxicity was observed in rabbits receiving a three-dose regimen of EBS-LASV. These studies demonstrate that EBS-LASV is safe when administered to animals and supported a first-in-human dose-escalation, safety, and immunogenicity clinical study."
Journal • Preclinical • Infectious Disease
May 07, 2023
Lassa fever vaccine candidates: A scoping review of vaccine clinical trials.
(PubMed, Trop Med Int Health)
- "Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging."
Journal • Review • Infectious Disease
1 to 3
Of
3
Go to page
1